1-3 of 3
Gail Morris, RN
Close
Sort by
Journal Articles

Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia.

Farhad Ravandi, MD, Stefan Faderl, MD, Deborah Thomas, MD, Jan Burger, MD, Charles Koller, MD, Guillermo Garcia-Manero, MD, Gail Morris, RN, Ritva Torma, RN, Hagop Kantarjian, MD, Jean-Pierre Issa, MD
Journal: Blood
Blood (2007) 110 (11): 897.
https://doi.org/10.1182/blood.V110.11.897.897
Published: 2007
Journal Articles

Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.

Guillermo Garcia-Manero, MD, Hui Yang, MD, PhD, Blanca Sanchez-Gonzalez, MD, Srdan Verstovsek, MD, Alessandra Ferrajoli, MD, Michael Keating, MD, Michael Andreeff, MD, Susan O’Brien, MD, Jorge Cortes, MD, William Wierda, MD, PhD, Stefan Faderl, MD, Charles Koller, MD, Jan Davis, RN, Gail Morris, RN, Jean-Pierre Issa, MD, Stanley R. Frankel, MD, Victoria Richon, PhD, Bernard Fine, PhD, Hagop Kantarjian, MD
Journal: Blood
Blood (2005) 106 (11): 2801.
https://doi.org/10.1182/blood.V106.11.2801.2801
Published: 2005
Journal Articles

Hypomethylation Dynamics Following Decitabine Therapy in Chronic Myelogenous Leukemia.

Jean-Pierre J. Issa, M.D., Vazganush Gharibyan, Ph.D., Jaroslav Jelinek, M.D., Ph.D., Gail Morris, RN, Srdan Verstovsek, M.D., Moshe Talpaz, M.D., Guillermo Garcia-Manero, M.D., Hagop M. Kantarjian, M.D.
Journal: Blood
Blood (2004) 104 (11): 2956.
https://doi.org/10.1182/blood.V104.11.2956.2956
Published: 2004